Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Gualdoni, Guido A ^a   Lingscheid, Tilman ^b   Schmetterer, Klaus G ^c   Hennig, Annika ^a   Steinberger, Peter ^a   Zlabinger, Gerhard J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CALCIUM; CASP4 PROTEIN, HUMAN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INITIATOR CASPASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROLIDE;

ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; MONOCYTE; MOUSE; SECRETION (PROCESS); SEPSIS; SIGNAL TRANSDUCTION;

ANIMALS; AZITHROMYCIN; CALCIUM; CASPASES, INITIATOR; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMASOMES; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROLIDES; MICE; MICE, INBRED C57BL; MONOCYTES; NF-KAPPA B; SEPSIS; SIGNAL TRANSDUCTION;

EID: 84936972916     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12016     Document Type: Article

References (45)

1. Kanoh, S. & Rubin, B. K. Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications. Clin. Microbiol. Rev. 23, 590-615 (2010).
2. Ratzinger, F. et al. Azithromycin suppresses CD4(+ ) T-cell activation by direct modulation of mTOR activity. Sci. Rep. 4, 7438 (2014).
3. Seemungal, T. A. R. et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178, 1139-1147 (2008).
4. Albert, R. K. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365, 689-698 (2011).
5. Banerjee, D., Honeybourne, D. & Khair, O. A. The effect of oral clarithromycin on bronchial airway inflammation in moderateto- severe stable COPD: a randomized controlled trial. Treat. Respir. Med. 3, 59-65 (2004).
6. Suzuki, T. et al. Erythromycin and common cold in COPD. Chest 120, 730-733 (2001).
7. Wong, C. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. The Lancet 380, 660-667 (2012).
8. Cai, Y. et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J. Antimicrob. Chemother. 66, 968-978 (2011).
9. Rollins, D. R., Good, J. T. & Martin, R. J. The role of atypical infections and macrolide therapy in patients with asthma. J. Allergy Clin. Immunol. Pract. 2, 511-517 (2014).
10. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
11. Aachoui, Y., Sagulenko, V., Miao, E. A. & Stacey, K. J. Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection. Curr. Opin. Microbiol. 16, 319-326 (2013).
12. Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013-1022 (2014).
13. Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR 4. Science 341, 1246-1249 (2013).
14. Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187-192 (2014).
15. Vladimer, G. I., Marty-Roix, R., Ghosh, S., Weng, D. & Lien, E. Inflammasomes and host defenses against bacterial infections. Curr. Opin. Microbiol. 16, 23-31 (2013).
16. Kebaier, C. et al. Staphylococcus aureus α -hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome. J. Infect. Dis. 205, 807-817 (2012).
17. Shaw, P. J., McDermott, M. F. & Kanneganti, T.-D. Inflammasomes and autoimmunity. Trends Mol. Med. 17, 57-64 (2011).
18. Jankovic, D. et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J. Exp. Med. 210, 1899-1910 (2013).
19. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
20. Brusselle, G. G., Provoost, S., Bracke, K. R., Kuchmiy, A. & Lamkanfi, M. Inflammasomes in respiratory disease: from bench to bedside. Chest 145, 1121-1133 (2014).
21. Pauwels, N. S. et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur. Respir. J. 38, 1019-1028 (2011).
22. Botelho, F. M. et al. IL-1α /IL-1R1 Expression in Chronic Obstructive Pulmonary Disease and Mechanistic Relevance to Smoke- Induced Neutrophilia in Mice. PLoS ONE 6, e28457 (2011).
23. Imaoka, H. et al. Interleukin-18 production and pulmonary function in COPD. Eur. Respir. J. 31, 287-297 (2008).
24. Eltom, S. et al. P2 × 7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PloS One 6, e24097 (2011).
25. Nambu, A. & Nakae, S. IL-1 and Allergy. Allergol. Int. Off. J. Jpn. Soc. Allergol. 59, 125-135 (2010).
26. Asgari, E. et al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122, 3473-3481 (2013).
27. Netea, M. G. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113, 2324-2335 (2009).
28. Labro, M. T. Intracellular bioactivity of macrolides. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 1 Suppl 1, S24-S30 (1996).
29. Bosnar, M., Kelnerić, Ž., Munić, V., Eraković, V. & Parnham, M. J. Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin. Antimicrob. Agents Chemother. 49, 2372-2377 (2005).
30. Mtairag, E. M., Abdelghaffar, H., Douhet, C. & Labro, M. T. Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Antimicrob. Agents Chemother. 39, 1676-1682 (1995).
31. Vazifeh, D., Abdelghaffar, H. & Labro, M. T. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother. 41, 2099-2107 (1997).
32. Restrepo, M. I. & Anzueto, A. Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? Am. J. Respir. Crit. Care Med. 190, 1-2 (2014).
33. Southern, K. W., Barker, P. M., Solis-Moya, A. & Patel, L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 11, CD002203 (2012).
34. Vrančić, M. et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br. J. Pharmacol. 165, 1348-1360 (2012).
35. Kikuchi, T. et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κ B transcription factors. J. Antimicrob. Chemother. 49, 745-755 (2002).
36. Khan, A., Slifer, T., Araujo, F. & Remington, J. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int. J. Antimicrob. Agents 11, 121-132 (1999).
37. Matzneller, P. et al. Blood, Tissue, and Intracellular Concentrations of Azithromycin during and after End of Therapy. Antimicrob. Agents Chemother. 57, 1736-1742 (2013).
38. Zeitlinger, M., Wagner, C. C. & Heinisch, B. Ketolides-the modern relatives of macrolides : the pharmacokinetic perspective. Clin. Pharmacokinet. 48, 23-38 (2009).
39. Amsden, G. W. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18 Suppl 1, S11-15 (2001).
40. Kobayashi, Y. et al. A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF-κ B Inhibition. J. Pharmacol. Exp. Ther. 345, 76-84 (2013).
41. Viganò, E. & Mortellaro, A. Caspase-11: the driving factor for noncanonical inflammasomes. Eur. J. Immunol. 43, 2240-2245 (2013).
42. Kajiwara, Y. et al. A critical role for human caspase-4 in endotoxin sensitivity. J. Immunol. Baltim. Md 1950 193, 335-343 (2014).
43. Sollberger, G., Strittmatter, G. E., Kistowska, M., French, L. E. & Beer, H.-D. Caspase-4 Is Required for Activation of Inflammasomes. J. Immunol. 188, 1992-2000 (2012).
44. Gualdoni, G. A. et al. Resveratrol enhances TNF-α production in human monocytes upon bacterial stimulation. Biochim. Biophys. Acta 1840, 95-105 (2014).
45. Jörgl, A. et al. Human Langerhans-cell activation triggered in vitro by conditionally expressed MKK6 is counterregulated by the downstream effector RelB. Blood 109, 185-193 (2007).